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Abstract
Background: Alcohol dependence is common and serious cause of social and physical harm. However, the optimal
management of those with moderate and severe alcohol dependence in primary and community care after
detoxification remains unclear. The aim of this review is to evaluate the effectiveness of interventions for
maintaining abstinence in people with alcohol dependence following detoxification.
Methods: We will systematically search electronic databases and clinical trial registries for randomized controlled
trials (RCTs) examining the effectiveness of pharmacological and/or psychosocial interventions for maintaining
abstinence in recently detoxified, alcohol-dependent adults. The searches will be complemented by checking
references and citations from included studies and other relevant systematic reviews. No limitation on language,
year, or publication status will be applied. RCTs will be selected using prespecified criteria. Descriptive information,
study characteristics, and results of eligible RCTs will be extracted. A revised version of the Cochrane Risk of Bias
tool (RoB 2.0) will be used to assess the risk of bias in eligible RCTs. Results will be synthesized and analyzed using
network meta-analysis (NMA). Overall strength of the evidence and publication bias will be evaluated. Subgroup
and sensitivity analysis will also be performed.
Discussion: This network meta-analysis aims to appraise and summarize the total evidence of therapeutic
interventions for alcohol-dependent patients that require support for detoxification and can be treated in the
community. The evidence will determine which combination of interventions are most promising for current
practice and further investigation.
Systematic review registration: PROSPERO CRD42016049779
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Background
Alcohol dependence is a long-term problematic pattern
of alcohol use leading to serious negative health out-
comes. Chronic and excessive alcohol use has been asso-
ciated with increased risk of cancer, diabetes, infectious
disease, cardiovascular disease, and neuropsychiatric dis-
ease [1]. The negative effects of alcohol on cognitive
processing and behavior also contribute to psychosocial
problems [2–4]. The consequence of these is a large cost
to social and healthcare systems [5]. Within the UK
alone, it is estimated that alcohol-related harm and pre-
scription items for treating alcohol dependence cost
around £21 and £4 billion per year, respectively [6, 7].
Management of alcohol dependence is challenging. In
the UK, only about 60% of alcohol-dependent patients
are completely free of dependency from alcohol after
treatment [8]. This indicates scope for improvement in
clinical outcomes. Many patients drop out of treatment,
particularly those exhibiting severe alcohol dependence
and comorbidities. This is not only wasteful of re-
sources, but clinically risky as repeated withdrawals
from alcohol are associated with an increase in the se-
verity of withdrawal symptoms and can precipitate poor
outcomes [9].
There is a growing trend away from inpatient to out-
patient treatment for alcohol-dependent patients [8].
For patients with moderate and severe dependence,
alcohol detoxification is a crucial part of management.
While the evidence supporting community detoxifica-
tion is robust [10–14], there is an evidence gap relating
to continuing care for detoxified patients in order to
maintain abstinence. Pharmacological interventions
including acamprosate, naltrexone, and disulfiram, in
conjunction with psychotherapy, have been recom-
mended [15]. However, it is not clear what works best
in non-inpatient settings, such as primary and commu-
nity care.
Several reviews have been undertaken of the effective-
ness of therapeutic interventions on maintaining abstin-
ence in detoxified alcohol-dependent patients [16–23].
Their conclusions were based on subgroup analyses of
pairwise meta-analyses of specific interventions, such as
acamprosate [16–22], naltrexone [16, 20], and sodium
oxybate [20, 21, 23]. However, the comparative efficacy of
these and other interventions has not been established.
Moreover, the effects of conjunct psychotherapy on the ef-
ficacy of interventions are underexplored. To date, it is
unclear how effective are pharmacotherapy and psycho-
therapy in maintaining abstinence for alcohol-dependent
adults in non-inpatient settings following detoxification.
The aim of this systematic review is thus to appraise and
summarize the total evidence of therapeutic interventions
for detoxified alcohol-dependent patients in primary and
community care settings.
Methods
Methods are derived from the Cochrane Handbook for
Systematic Reviews of Interventions [24]. The reported
items are in compliance with the Preferred Reporting
Items for Systematic Reviews and Meta-Analysis Protocol
(PRISMA-P) [25]. The PRISMA-P checklist can be
found in Additional file 1. This review protocol has
been registered with the International Prospective
Register of Systematic Reviews (PROSPERO) on 25
October 2016 (registration number CRD42016049779).
Any amendments to this protocol will be described in
the final review.
Eligibility criteria
Study design
We will include both individualized and cluster random-
ized controlled trials (RCTs).
Population
Eligible populations are adults aged over 18 years with
alcohol dependence, diagnosed using standardized diag-
nostic criteria (e.g., Diagnostic and Statistical Manual of
Mental Disorders (DSM), International Classification of
Diseases (ICD)), or the Alcohol Use Disorders Identifica-
tion Test (AUDIT; score ≥20), who have undergone
detoxification in less than 4 weeks. Studies including
pregnant women will be excluded.
Interventions/comparators
We will include any therapeutic intervention for maintain-
ing abstinence in alcohol-dependent adults. Interventions
should be applicable to non-inpatient settings (such as
primary care and community settings). The following in-
terventions will be considered but the list is not exhaustive
and interventions will be added when identified through
searches:
1. Opioid antagonists: naltrexone, nalmefene
2. Anticonvulsants: valproates, pregabalin, topiramate,
levetiracetam, oxcarbazepine, gabapentin
3. Antidepressants: sertraline, fluoxetine, escitalopram,
paroxetine, citalopram, desipramine
4. Antipsychotics: olanzapine, tiapride, aripiprazole
5. Alcohol deterrents: disulfiram, acamprosate, calcium
carbimide
6. Miscellaneous agents: baclofen, sodium oxybate,
ondansetron, varenicline, nefazodone
7. Psychotherapies: cognitive behavioral therapy (CBT),
motivational enhancement therapy (MET), 12-step
facilitation therapy, coping skills, motivational
interviewing
8. Concomitant or adjunctive therapies: naltrexone and
CBT, acamprosate and CBT, naltrexone and sodium
oxybate
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We aim to compare interventions with placebo or
other interventions using network meta-analysis (NMA)
within the frequentist framework.
Outcomes
The primary outcome is abstinence at least 12 weeks
after randomization. There are two main reasons for
this. First, abstinence is the most appropriate and
commonly reported outcome for severely dependent
drinkers. Second, completely abstaining from alcohol
has been shown to improve cognitive function [26, 27]
and quality of life [28–30].
Secondary outcomes that will be considered are (1)
amount of alcohol consumption, (2) drinking frequency,
(3) intervention compliance, (4) adverse events, and (5)
withdrawal from study.
Depending on the length of follow-up reported, the
end-points for each outcome will be categorized into
short-term (12 to 20 weeks), intermediate-term (20 to
36 weeks), and long-term (more than 36 weeks). Longer
follow-up periods will also be considered.
Search strategy
Electronic searches will be conducted using the following
bibliographic databases: Cochrane Central Register of Con-
trolled Trials (CENTRAL), Ovid Embase, MEDLINE, and
PsycINFO. The search will start from inception of each
database and be updated toward the end of the review.
Search strategies will be developed and applied by an
information specialist. These strategies will be based on
a combination of controlled vocabulary and keywords
according to the Cochrane Handbook [31]. We will not
restrict search strategies by language, date, or publica-
tion status. The strategy developed for Ovid MEDLINE
will be adapted for other databases. The Ovid MEDLINE
search strategy can be found in Additional file 2. Refer-
ence lists and citations from all included studies will be
hand-searched to identify further studies.
Reference lists from other systematic reviews and meta-
analyses will be examined to identify further eligible stud-
ies. The reviews will be identified from the primary
searches used to identify RCTs, the Cochrane Database of
Systematic Reviews (CDSR) and Epistemonikos. We will
also conduct a separate search on Ovid MEDLNE using a
systematic review filter.
Trial registries (i.e., ClinicalTrials.gov, EU Clinical Trials
Register (EudraCT), and the World Health Organization
International Clinical Trials Registry Platform (ICTRP))
will be searched to identify relevant registered trials and
reports.
Study selection
Search results will initially be managed using Endnote. A
bespoke Excel spreadsheet will be used for study selection
against a predefined set of inclusion and exclusion cri-
teria. The selection of references will go through two
screening processes: an initial screening and a full-text
examination. During the initial screening, a team of six
reviewers will independently screen titles and abstracts
using the inclusion and exclusion criteria to remove ir-
relevant references. At least a third of references will be
dual-screened. Any disagreement between reviewers
will be resolved by discussion or consultation with a
third reviewer. The consistency of agreement amongst
reviewers is maintained by pairing the first author with
other reviewers in the majority of the initial screening.
If there is insufficient information in the title and
abstract to make a decision, the full-text will be re-
trieved. References thought to be potentially relevant in
languages not known by reviewers will be translated,
and initial screening will take place using the same
procedure.
Studies passed through initial screening will then be
subject to full-text examination. In this stage, four re-
viewers will be involved in identification of eligible
studies using an independent, dual-screening approach.
The first author will pair with other reviewers to dual-
screen full-text, to minimize interrater variation. Any
disagreement between pairs will be resolved by discus-
sion or, if unresolved, by consulting a senior author.
Reasons for studies excluded during this stage will be
documented and reported. A PRISMA flow diagram
will be used to document the flow of records [32].
Data extraction
Data from studies that meet the inclusion criteria and with
sufficient information of study description, participant
characteristics, definitions of outcome measures, and out-
come results will be extracted independently by two re-
viewers using a pilot-tested data extraction form. The first
author will extract information from all reports, pairing
with one of three other reviewers to dual-extract data.
Any disagreement will be discussed and, if necessary, a se-
nior author will be consulted to achieve consensus. When
there are multiple publications from the same study, all
publications will be examined and only the most compre-
hensive or up-to-date information will be extracted to en-
sure that the study is not over-represented in the review.
Data extracted from each study will include the
following:
1. General information (e.g., year, lead author, study
title, unique identifier from ClinicalTrials.gov or
equivalent)
2. Study information (e.g., country, setting, recruitment,
screening process, duration, use of diagnostic criteria,
inclusion criteria, exclusion criteria)
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3. Participant characteristics (e.g., number, age, gender,
severity of alcohol dependence, baseline drinking
behaviors, social background, primary diagnosis,
comorbid diagnoses, concurrent substance abuse)
4. Interventions and comparator (e.g., types, regimes,
additional treatment, length)
5. Outcome measures and assessment methods
6. Details for risk of bias assessment (e.g., randomization
methods, blinding, intention-to-treat analysis, use of
methods for handling missing data and dropout)
7. Source of funding
Dealing with missing data
We will contact corresponding authors of included studies
to obtain any unreported and missing data. Our primary
interest is the effect of assignment to intervention, so we
will seek results for the intention-to-treat population. If
data are missing due to participant drop out, we will use
reported results for participants that completed the study.
A sensitivity analysis for unreported and missing data will
be performed, and any issues will be recorded using the
approaches adapted from the Cochrane Handbook [33].
Assessment of risk of bias
The risk of bias in each study will be assessed using a
recently developed revision of the Cochrane risk of bias
tool (RoB 2.0: a revised tool to assess risk of bias in ran-
domized trials) [34]. Two pairs of reviewers will independ-
ently assess five domains of bias for each outcome. These
five domains are bias due to (1) the randomization
process, (2) deviations from intended interventions, (3)
missing outcome data, (4) measurement of the outcome,
and (5) selection of the reported results.
Answers to signaling questions and supporting infor-
mation will collectively lead to a domain-level judgment
in the form of “Low Risk,” “Some Concerns”, or “High
Risk” of bias. These domain-level judgements will in-
form an overall risk of bias judgment for the outcome.
Discrepancies between the two reviewers will be resolved
by discussion to reach consensus. If necessary, a third
reviewer will be consulted to achieve a decision.
For each outcome, we will assess the quality of the evi-
dence of the NMA results using an adapted version of the
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) methodology [35]. We produce
a “summary of findings table” for each clinical recommen-
dation outcome [36].
To assess publication biases, we plan to conduct the
assessment through “comparison-adjusted” [37] and
“contour-enhanced” [38] funnel plots if we find sufficient
studies. If asymmetry is found, we will examine variation
of the studies to elucidate whether the cause of asymmetry
is likely due to publication bias or a real relationship
between trial size and effect.
Data synthesis
Considering the large body of literature in this topic, we
plan to combine and compare all interventions using
NMA. We will analyze each identified interventions as a
different “node” in the network. Different doses or
exposure times of the same pharmacological or psycho-
social interventions will be categorized into a small
number of nodes according to the length, strength, and
clinical consideration. Control groups in studies of
pharmacological and psychosocial interventions may be
rather different, and we will treat these as separate nodes
in the network. For interventions that cannot be included
in the NMA model, their results will be summarized and
narratively described in the final review if it is possible.
NMA rests on an assumption of transitivity or ex-
changeability across studies, which implies that any pa-
tient in the network could have been assigned to any of
the interventions in the network. To maximize the val-
idity of this assumption, we are focusing the review on
a specific population (detoxified, alcohol-dependent pa-
tients) in a specific setting (community non-inpatient
settings). However, we expect that some clinical and
methodological variables, including social background,
comorbid diagnoses, and co-interventions, may influ-
ence the effectiveness or acceptability of the interven-
tions of interest. We plan to investigate the clinical and
methodological comparability across interventions to
assure transitivity after data extraction [39].
We will generate a table of descriptive characteristics
for included studies. Relevant outcome data will be syn-
thesized by using odds ratios (ORs) for dichotomous
outcomes and standardized mean differences (SMDs) for
continuous measures. The estimated treatment effects
from included studies, along with 95% confidence inter-
vals (CIs), will be plotted for each pairwise comparison
for inspection of heterogeneity across studies.
We will examine pairwise comparisons for each inter-
vention across studies for each outcome, in order to as-
sess statistical heterogeneity. Heterogeneity variances
obtained from these pairwise comparisons will be used
to investigate the possibility of statistical heterogeneity.
The inconsistency in the NMA, referring to the degree
of disagreement between source-specific treatment ef-
fects [39], will be evaluated locally by comparing the
direct and indirect summary effect estimates across
studies using the node-split approach [40] and globally by
using the design-by-treatment interaction model [41, 42].
The NMA will be based on random-effects models to
account for heterogeneity in treatment effects within each
comparison, assuming a common heterogeneity variance
(τ2) across all comparisons [35]. We intend to perform
our NMA model with contrast-level data by using multi-
variate meta-analysis approaches within the frequentist
framework in STATA [43]. We will use the network
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suite of STATA commands [44]. The restricted max-
imum likelihood method will be used to estimate
between-study variance in the NMA. However, this is
subject to the data and structure of the network. The
final statistical approaches and strategy will be devel-
oped by experienced statisticians at a further stage in
the review. The summary ORs or SMDs, including the
95% CIs, for all comparisons will be presented in a
summary table for each outcome. Furthermore, we will
provide ranking probabilities for interventions in ran-
kograms and cumulative ranking probability plots for
the primary outcome [45].
Subgroup and sensitivity analysis
Given the variety of study settings in the literature, we
plan to perform subgroup analyses for the primary out-
come using random-effects meta-regression approaches
[46]. Potential variables used for subgrouping will include
length of intervention, optional psychosocial interven-
tions, dosing and schedule of interventions, psychiatric
co-morbidity, severity of alcohol dependence, and social
background. Sensitivity analyses will be conducted to ex-
plore the impact of imputation and risk of bias on out-
come data.
Discussion
This review will assess the comparative effectiveness of
therapeutic interventions to maintain abstinence for
alcohol-dependent patients following detoxification in
community non-inpatient settings. Currently, there is
no comprehensive systematic review of interventions
across different pharmacological and psychosocial mo-
dalities to inform the clinical practice for the treatment
of alcohol dependence in detoxified patients. A system-
atic review specifically bridging the gap between detoxi-
fication and alcohol dependence treatment has not
been undertaken, to our knowledge. Maisel et al. con-
ducted a meta-analysis to examine effects of different
moderators on the efficacy of n altrexone and acampro-
sate on alcohol use disorders [16]. However, there are lim-
itations to the clinical application of their conclusions as
they did not assess risk of bias in the individual studies.
Timko et al. identified factors affecting detoxification
completion and subsequent treatment in detoxified
alcohol-dependent patients [47]. However, their evidence
review was based on searches of a single database. Other
systematic reviews have applied subgroup analyses to in-
vestigate the effect of detoxification on specific interven-
tions [18, 19, 23]. The application of these conclusions is
often limited and less likely to be useful for community
settings, which present a wide range of patient types and
treatment options. The advantage of the network meta-
analysis approach is that it offers the opportunity to per-
form more complex comparisons and compute a ranking
effectiveness for interventions. The direct and indirect
comparisons evaluating evidences amongst licensed, off-
license use medications, and psychosocial interventions
enable us to infer appropriate interventions in community
settings. Therefore, this evidence will help patients and cli-
nicians to make decisions in such settings. The results will
also aid to the development and optimization of new
interventions.
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